Business Responsibility and Sustainability Reporting (BRSR) for the financial year 2024-25.
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Abbott India has submitted its mandatory BRSR for FY 2024-25, covering the period April 1, 2024 to March 31, 2025, along with an independent assurance statement from DNV Business Assurance. The company reported a turnover of ₹6,345.40 Crores and net worth of ₹4,233.15 Crores, with a workforce of 3,438 permanent employees and 273 workers. Key ESG highlights include a 69% reduction in Scope 2 carbon emissions at its BKC office against the 2018 baseline, 324 MWh of solar energy generated at the Goa plant, Zero Waste-to-Landfill certification at the Goa plant and BKC office, and CSR initiatives that upgraded 170 Primary Health Centres and screened over 8.46 lakh patients for non-communicable diseases. Three GST penalties totaling about ₹1.31 Crores were disclosed (under appeal), related to input tax credit disputes. The company also launched seven new products in FY25, including the PneumoShield 14 vaccine and Vonefi for GERD.
This is a routine annual regulatory compliance filing and is unlikely to move the stock on its own. It reinforces Abbott India's ESG credentials for institutional and ESG-focused investors, while the disclosed GST penalties are immaterial to overall financials and are being contested.